A pharmaceutical company does not need thousands of products to have a product-complexity problem. One therapy can quickly become multiple strengths, dosage forms, pack sizes, market-specific labels and regulatory configurations. Each variant may share some materials and production steps while diverging at others. On a product list, the portfolio can still look manageable. In the planning model, it has already become a web of dependencies.
That complexity rarely arrives all at once. It accumulates quietly as the business launches into a new market, adds a contract manufacturer, introduces a different pack configuration or responds to a regulatory requirement. Each decision is reasonable in isolation. Together, they create more ways for demand, supply, inventory and capacity to fall out of alignment.
The resulting planning problems are often misdiagnosed. Forecast accuracy appears to be the issue. Inventory seems too high. Service becomes inconsistent. Planners spend more time expediting, reconciling and explaining exceptions. Yet these are frequently symptoms of a deeper problem: the planning process cannot evaluate all the relationships that determine whether a product will actually be available where and when it is needed.
In pharmaceutical supply chains, the commercial product is only the visible end of a much longer chain. A finished pack may depend on a common active ingredient, a shared intermediate, a specific production line, quality release, market authorization, packaging components and remaining shelf life. A delay at any point can affect several downstream products, but not necessarily in the same way or at the same time.
This is what makes product complexity different from simple SKU proliferation. The challenge is not merely the number of items. It is the number of relationships among them. Shared materials create competition for constrained supply. Postponed packaging creates flexibility, but only if planners can see where inventory can still be redirected. Market-specific requirements limit substitution. Shelf-life rules turn time into a hard constraint. A plan that looks feasible at an aggregate level can break when those details are applied.
The impact becomes especially visible when conditions change. A batch delay is not just a late order. It can change launch readiness, allocation priorities, inventory exposure and customer commitments across several markets. A demand increase in one country may consume supply intended for another. A packaging constraint may leave usable bulk product waiting while finished-goods availability deteriorates. The business needs to understand those consequences before choosing a response.
ERP systems remain essential for recording transactions, managing inventory and tracking production. But product complexity creates a forward-looking decision problem. Planners must determine which dependencies matter, where risk will surface and how one choice changes the rest of the plan. Transactional visibility alone does not answer those questions.
Spreadsheets often fill the gap because they give experienced planners room to apply judgment. Over time, however, the logic becomes distributed across files, functions and individuals. One planner understands the relationship between bulk inventory and country packs. Another knows which production constraint will matter first. A third maintains the assumptions behind launch demand. The process may continue to work, but it becomes harder to see the whole picture, evaluate alternatives consistently or respond at the speed the business requires.
That is why product complexity can quietly break planning long before a dramatic failure occurs. The warning signs are usually operational: excess inventory and shortages coexist; feasible plans require repeated manual intervention; scenario analysis takes days; and small changes create disproportionate disruption. The organization has data, but not a dependable way to translate that data into coordinated decisions.
A stronger approach begins by representing the relationships that shape availability, not simply reproducing the item master in another system. Demand, supply, inventory and capacity need to be evaluated together, with enough product and market detail to expose meaningful constraints. Planners also need to test alternatives quickly: What happens if a batch slips? Which demand should receive constrained supply? Can available inventory be redirected? What is the service and expiry impact of each choice?
This does not mean every pharmaceutical company needs the largest possible transformation. In fact, trying to model every exception at once can delay value and recreate complexity inside the implementation. The better path is to identify the product relationships and decisions that matter most, establish a credible planning foundation and expand from there.
Kinaxis Planning One provides a practical path into advanced planning by bringing demand forecasting, supply planning, inventory optimization and scenario analysis into a common environment. For pharmaceutical organizations moving beyond spreadsheets or primarily transactional planning, that creates the ability to evaluate how a change moves across the plan rather than discovering the consequences function by function.
Technology alone is not the answer. The model must reflect how the business actually plans, the data must be ready for the decisions it needs to support and planners must trust the outputs enough to use them. neos by Argon & Co combines Kinaxis implementation experience with supply chain planning, process design and operational expertise to help organizations build that foundation and move toward value without making the first step larger than it needs to be.
Product complexity is not inherently a problem. It enables market growth, patient choice and portfolio expansion. The risk appears when the planning process can no longer see how the pieces interact.
Pharmaceutical companies do not need to eliminate complexity. They need to make it visible, evaluate its consequences and respond with confidence. When the planning model reflects the real relationships behind the product, teams can move beyond explaining what happened and begin shaping what happens next.
Ready to make product complexity more manageable?
Talk with neos by Argon & Co about a practical path to advanced pharmaceutical planning with Kinaxis Planning One.
